Daniel Vasella in Reuters The margins are higher than our pharma business and are obviously very attractive,Novartis Chief Executive Daniel Vasella told reporters.
Carl Icahn in San Francisco Chronicle Over the past decade, we have recognised the high growth trajectory of bio-pharma business verticals and progressively invested in building proprietary know-how and global scale. We believe this is the right time to divest our enzymes business and... Kiran Mazumdar-Shaw http://www.google.com/url?q=http://en.wikipedia.org/wiki/Kiran_Mazumdar-Shaw&source=dictionary&usg=AFQjCNEYFCnTn2HKU1fE5pKyi1-2BZUY7w Business Standard http://www.google.com/url?q=http://www.business-standard.com/common/storypage.php%3Fautono%3D291654%26leftnm%3D1%26subLeft%3D0%26chkFlg%3D&source=dictionary&usg=AFQjCNHNm_17v5cO0x45n3V1AdkXgTDwGQ Jul 18, 2007
74064 99213 pharma Negotiations between the parties are under way and the large pharma company has requested that ImClone not divulge its name until negotiations are completed," the statement, which the company attributed to Icahn, said.